AJP Author Spotlight: The Evidence for Ketamine and Esketamine in Treatment-Resistant Depression

August 2020 AJP Editor Spotlight: Brain Stimulation Therapy for Treatment-Resistant DepressionПодробнее

AJP Author Spotlight: Improving Suicide Prevention Through Evidence-Based StrategiesПодробнее

Ketamine and Esketamine for depression. What does the evidence say?Подробнее

Ketamine for treatment resistant depressionПодробнее

872 - Ketamine and EsketamineПодробнее

Health Spotlight: Ketamine works on treatment-resistant depressionПодробнее

May 2019 AJP Editor Spotlight: VEGF Signaling in the Prefrontal Cortex and Effects of KetamineПодробнее

May 2021 AJP Editor Spotlight: Impact of Ezogabine on Reward Circuit Activity, Depressive SymptomsПодробнее

Treatment Resistant Depression and Ketamine TherapyПодробнее

Midwest CEPAC: Evidence Presentation, Treatment-Resistant DepressionПодробнее

#22: esketamine (Spravato) | For Major & Treatment-Resistant Depression | Drug Cards DailyПодробнее

Ketamine for Treatment Resistant DepressionПодробнее

WHAT DOES ESKETAMINE (SPRAVATO) TREAT?Подробнее

Ketamine & Depression: How it Works - Yale Medicine ExplainsПодробнее

February 2021 AJP Editor Spotlight: Repeated Ketamine Administration for Chronic PTSDПодробнее

Ketamine and Treatment-Resistant DepressionПодробнее

Latest in mental health treatment | Spravato nasal spray for depression #EsketamineTreatmentПодробнее

Spravato and KetamineПодробнее